



Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort

Vincent Cottin, Sonia Gueguen, Stéphane Jouneau, Hilario Nunes, Bruno Crestani, Philippe Bonniaud, Lidwine Wemeau-Stervinou, Martine Reynaud-Gaubert, Dominique Israel-Biet, Jacques Cadranel, et al.

► To cite this version:

Vincent Cottin, Sonia Gueguen, Stéphane Jouneau, Hilario Nunes, Bruno Crestani, et al.. Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort. *Respiration*, 2022, 101 (1), pp.34-45. 10.1159/000518008 . hal-03361027

HAL Id: hal-03361027

<https://hal.science/hal-03361027>

Submitted on 26 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Research article

Impact of gender on the characteristics of patients with idiopathic pulmonary fibrosis included in the RaDiCo-ILD cohort

Vincent Cottin^a, Sonia Gueguen^b, Stéphane Jouneau^c, Hilario Nunes^d, Bruno Crestani^e,
Philippe Bonniaud^f, Lidwine Wémeau-Stervinou^g, Martine Reynaud-Gaubert^h, Dominique
Israël-Bietⁱ, Jacques Cadranel^j, Sylvain Marchand-Adam^k, Sébastien Quétant^l, Sandrine
Hirschi^m, David Montaniⁿ, Anne-Sophie Gamez^o, Marie Chevereau^b, Isabelle Dufaure-Garé^b,
Serge Amselem^p, Annick Clément^q and the OrphaLung and RespiFil networks

^aHôpital Louis Pradel, Centre Coordinateur National de Référence des Maladies
Pulmonaires Rares, Hospices Civils de Lyon, UMR754, Université de Lyon, INRAE,
OrphaLung, RespiFil, Lyon, France; ^bInserm U933, RaDiCo, French National Program on
Rare Disease Cohorts, Hôpital Trousseau, Paris, France; ^cHôpital Pontchaillou - CHU de
Rennes, IRSET UMR 1085, Université de Rennes 1, Rennes, France; ^dAssistance Publique
Hôpitaux de Paris, Service de Pneumologie, Centre de Référence des Maladies
Pulmonaires Rares (Site Constitutif), Hôpital Avicenne, Inserm UMR1272, Université
Sorbonne Paris Nord, Bobigny, France; ^eUniversité de Paris, Inserm U1152, Assistance
Publique Hôpitaux de Paris, Hôpital Bichat, Centre de Référence (Site Constitutif) Maladies
Pulmonaires Rares, Paris, France; ^fCentre de Référence (Site Constitutif) Maladies
Pulmonaires Rares, Service de Pneumologie et Soins Intensifs Respiratoires, CHU Dijon-
Bourgogne, Université Bourgogne-Franche Comté, Inserm U1231, Dijon, France; ^gService
de Pneumologie et Immuno-Allergologie, Centre de Référence (Site Constitutif) Maladies
Pulmonaires Rares, CHU de Lille, Lille, France; ^hService de Pneumologie, Hôpital Nord,
Marseille, France; ⁱAssistance Publique Hôpitaux de Paris, Hôpital Européen Georges
Pompidou, Service de Pneumologie, Université de Paris, Paris, France; ^jAssistance
Publique Hôpitaux de Paris, Service de Pneumologie et Oncologie Thoracique, Centre de
Référence (Site Constitutif) Maladies Pulmonaires Rares, Hôpital Tenon and Sorbonne
Université, Paris, France; ^kUniversité François Rabelais, Inserm U1100; Service de

Pneumologie, CHRU de Tours, Tours, France; ^lService Hospitalo-Universitaire de
Pneumologie et Physiologie, Pôle Thorax et Vaisseaux, Centre hospitalier universitaire de
Grenoble-Alpes, La Tronche, France; ^mService de Pneumologie, Centre Hospitalier
Universitaire (CHU) Strasbourg, Strasbourg, France; ⁿUniversité Paris–Saclay, Assistance
Publique Hôpitaux de Paris, Inserm UMR_S 999, Service de Pneumologie et Soins Intensifs
Respiratoires, Hôpital de Bicêtre, Le Kremlin Bicêtre, France; ^oService de Pneumologie,
CHU Montpellier, Montpellier, France; ^pSorbonne Université, Inserm U933, RaDiCo, French
National Program on Rare Disease Cohorts, Hôpital Trousseau, Paris, France; ^qSorbonne
Université, Assistance Publique Hôpitaux de Paris, Hôpital Trousseau, Service de
Pneumologie Pédiatrique, Centre de Référence des Maladies Respiratoires Rares, Paris,
France.

Running head: Idiopathic pulmonary fibrosis and gender in the RaDiCo-ILD cohort

Corresponding author: Vincent Cottin, MD PhD, Louis Pradel Hospital, Department of
Respiratory Medicine, 28 Avenue du Doyen Lepine, Lyon, F- 69677, France.
Email: vincent.cottin@chu-lyon.fr. Tel: +33427857700

Number of tables: 5

Number of figures: 1

Word count: 3,934

Keywords: idiopathic pulmonary fibrosis; idiopathic interstitial pneumonia; registry; gender;
patient characteristics; France [3–6 keywords]

Abstract

Background: There is growing evidence of gender-specific phenotypic differences amongst patients with idiopathic pulmonary fibrosis (IPF), which may affect patient outcomes.

Objectives: We present the characteristics of patients with IPF at inclusion in the French Rare Disease Cohort – Interstitial Lung Disease (RaDiCo-ILD) with the aim of characterising gender-specific phenotypic differences.

Methods: Patients with IPF who were enrolled in the national, multicentre RaDiCo-ILD cohort were included. Demographic characteristics, comorbidities, health-related quality of life (HRQoL) scores, pulmonary function, chest imaging and IPF treatment were collected at inclusion and described by gender.

Results: The cohort included 724 patients with IPF (54% of RaDiCo-ILD cohort), of whom 82.9% were male. The proportion of male and female patients with a prior history of smoking was 75.0% and 26.8%, respectively. Emphysema was present in 17.0% (95% confidence interval [CI]: 10.0, 24.0) of men and 5.4% (95% CI: 1.2, 9.6) of women. At inclusion, females had poorer HRQoL than males based on St. George's Respiratory Questionnaire scores (48.5 [95% CI: 43.9, 53.0] and 41.5 [39.4, 43.6], respectively). The mean forced vital capacity percent predicted was 77.7% (95% CI: 76.2, 79.3) and 87.4% (83.4, 91.4) for males and females, respectively. Honeycombing on high-resolution computed tomography (HRCT) was present in 70.8% (95% CI: 61.0, 80.6) of males and 45.8% (95% CI: 35.1, 56.5) of females.

Conclusions: This analysis of patients with IPF at inclusion in the RaDiCo-ILD cohort provides evidence that comorbid emphysema, lung volume reduction and honeycombing on HRCT are more common characteristics of males than females.

Trial registration: ClinicalTrials.gov (NCT04238871).

Introduction

Idiopathic pulmonary fibrosis (IPF), the most common and aggressive type of idiopathic interstitial pneumonia (IIP), is a chronic and progressive interstitial lung disease (ILD) of unknown aetiology [1]. It is characterised by progressive fibrosis on high-resolution computed tomography (HRCT), irreversible decline in lung function and worsening respiratory symptoms, and a high rate of mortality [1, 2]. Historically, patients with IPF survived for a median of 2–3 years following diagnosis of IPF [1]; however, increased recognition, earlier diagnosis and the availability of antifibrotic therapy have improved survival over the last 5 years [3, 2, 4].

IPF occurs predominantly in men, who account for approximately 70% of all cases [1, 3, 5]. The reason for this gender disparity is still largely unknown, but it has been hypothesised that greater male exposure to cigarette smoke and environmental and occupational risk factors may play a role [6]. The Gender, Age, Physiology (GAP) index and scoring system has acknowledged gender as an important determinant of outcome in IPF, with male sex, older age (>65 years) and poor pulmonary function associated with a higher risk of mortality [7]. Recent studies have further demonstrated that patient sex can have clinical and prognostic implications in IPF, with significantly poorer lung function observed in males compared with females at registry inclusion [8] and 40% higher risk of death or lung transplantation [5].

Patient registries enable the systematic collection of real-world data, which can provide valuable insights into the clinical course of diseases and the health status of a defined population of patients. They also serve as tools to retrospectively evaluate the clinical effectiveness and safety of medical interventions [9, 10]. For rare diseases such as IPF, in which the estimated global prevalence is just 3–9 cases per 100,000 people per year, registries are particularly useful [11, 12]. In recent years, a number of IPF registries have been initiated across the world, collecting cumulative data on thousands of patients, thereby

providing novel insights into the natural course of the disease and clinical management of IPF [9].

To date, there have been a small number of epidemiological studies in France. An observational study of patients with ILD in a French, urban, multi-ethnic county in the Paris area demonstrated a relatively low overall IPF prevalence (2.8 per 100,000 people per year), with a predominance in older males [12]. Gender was found to have a significant effect on baseline disease presentation and outcomes in a French, prospective IPF cohort (COhorte Fibrose [COFI]), which included 236 patients with incident IPF who did not receive antifibrotic therapy. Male patients had poorer lung function at IPF diagnosis and greater exposure to tobacco and occupational aero-contaminants compared with females, although female exposure to aero-contaminants may not have been fully captured [unpublished].

The Rare Disease Cohort – Interstitial Lung Disease (RaDiCo-ILD) was launched in 2017 as part of the RaDiCo research programme, co-ordinated by the Institut National de la Santé et de la Recherche Médicale in France (<https://radico.fr/fr/>). The overarching objectives of this national cohort study are to characterise and monitor the phenotypic features associated with IIP in France and to describe the natural history of the various forms of these diseases. More specifically in this study, we present the characteristics of patients at inclusion to this cohort who have a clinical diagnosis of IPF, with the aim of characterising gender differences.

Materials and methods

The RaDiCo-ILD cohort

RaDiCo-ILD is a national, multicentre, non-interventional cohort study in France. The majority of participating centres are part of the French national networks of reference and competence centres for rare respiratory diseases (OrphaLung and Rare Respiratory

Diseases Healthcare Faculty [RespiFIL] networks). The full list of participating centres and investigators is included in **Supplementary Table S1**.

For the RaDiCo-ILD cohort, all incident and prevalent patients who met the following criteria could be included: (1) a diagnosis of IIP established on presenting history, clinical, radiological, functional and, if available, pathological findings (for full criteria see **Supplementary Methods**); and (2) patients affiliated to a public health insurance provider. The RaDiCo-ILD study was registered with ClinicalTrials.gov (NCT04238871).

IPF cohort

The IPF cohort was a subgroup of patients included in the RaDiCo-ILD study. All patients in the IPF cohort who met the following criteria were included in the present study: (1) aged >18 years; (2) IPF diagnosed using the American Thoracic Society/European Respiratory Society (ATS/ERS) 2011 criteria [1] (until the revision of criteria in September 2018, which was subsequently used, allowing for the inclusion of patients with a diagnosis of probable IPF [13]); and (3) completion of a pulmonary function test (PFT) at inclusion visit. A multidisciplinary discussion was recommended to obtain a diagnosis, based on clinical signs, radiological investigation and surgical biopsy.

The study data were collected and managed using Research Electronic Data Capture (REDCap) tools hosted at Inserm UMR S 933 RaDiCo. REDCap is a secure, web-based application designed to support data capture for research studies. Data management was compliant with General Data Protection Regulation.

Statistical analyses

The analyses in this study were mainly descriptive and were performed with SAS® 9.4 software. The characteristics of patients with IPF were described. For continuous variables,

the number, number of missing values, median (range) or mean (standard deviation) according to the normality of the distribution, and 95% confidence interval (CI) of the means were included. For categorical variables, the number, percentage and 95% CI of the proportion were included. Data including demographic characteristics, significant comorbidities, pulmonary function testing, chest imaging, health-related quality of life (HRQoL) and IPF treatment were collected at inclusion visit and described by gender. Comorbidities at inclusion were recorded by investigators as present or absent. HRCT scans were obtained and analysed in each reference centre by each investigator independently, according to ATS/ERS recommendations. Although the study was not powered to assess the significance of gender comparisons, the population was described according to gender and the 95% CIs were calculated. An absence of confidence interval overlap between gender subgroups was considered a statistically significant difference.

Results of predictive prognostic measures were collected, including normalised 6-minute walk test (6MWT) values and GAP index scores and stages. To normalise the score with age and stature, the 6MWT is expressed as a percentage of the predicted value of a corresponding healthy subject [14]. The GAP index stratifies patients into three stages of increasing risk: Stage I with 0–3 points, Stage II with 4–5 points, and Stage III with 6–8 points [7].

Measures of HRQoL included the 36-Item Short Form survey (SF-36) and St. George's Respiratory Questionnaire (SGRQ) [15], with higher SF-36 scores and lower SGRQ scores indicating better health status.

Results

Of 1,345 patients with ILD enrolled in the RaDiCo-ILD registry between 3 July 2017 and 28 September 2020, 963 were adult patients with IPF (83% male, 17% female). Of these, 724

patients had completed PFTs and were therefore included in this analysis. The gender distribution was 600 males (83%) and 124 females (17%) (Figure 1).

Demographic and diagnostic characteristics at inclusion

Patient demographics for all patients with IPF are presented in Table 1. In the whole cohort, the mean age at diagnosis was 70.9 years and was similar for males and females (70.7 [95% CI: 70.0, 71.3] and 72.1 [95% CI: 70.5, 73.7] years, respectively). The median time period between diagnosis and cohort inclusion was 7.8 months (interquartile range [IQR]: 0.5–25.4). The median time between first symptom and a diagnosis of IPF was 2.0 years (IQR: 1.0–4.0) for both male and female patients. The overall mean body mass index was 26.9 kg/m² (26.8 kg/m² [95% CI: 26.4, 27.1] for male patients and 27.6 kg/m² [95% CI: 26.7, 28.6] for female patients) indicating that most were in the overweight range. Consistent with current practice, lung biopsies were performed in 24.1% of patients, and no significant differences were observed between male and female patients (22.9% [95% CI: 15.5, 30.4] and 29.5 [95% CI: 21.4, 37.6], respectively).

Patient comorbidities at inclusion

Comorbidities at inclusion are presented in Table 1. The most common conditions recorded were arterial hypertension (43.9%), gastroesophageal reflux disease (GERD; 26.4%) and diabetes (23.3%). Of the total cohort, 22.0% had existing coronary heart disease, recorded in a significantly higher proportion of male patients (24.6% [95% CI: 17.0, 32.2]) than female patients (9.8% [95% CI: 4.5, 15.0]). At inclusion, 15.0% of patients had emphysema (unadjusted for tobacco use), and it was also significantly more common in male patients than female patients (17.0% [95% CI: 10.0, 24.0] and 5.4% [95% CI: 1.2, 9.6], respectively). Thyroid dysfunction, which was hypothyroidism in most cases, was recorded in 8.7% of the

total cohort, affecting 5.8% (95% CI: 1.7, 10.0) and 22.6% (95% CI: 15.2, 29.9) of male and female patients, respectively.

The proportion of active tobacco smokers was 5.3% (95% CI: 1.4, 9.3) and 8.1% (95% CI: 3.3, 13.0) in the male and female populations, respectively. More than half of female patients (52.9% [95% CI: 44.0, 61.7]) had never smoked (defined as having less than 100 cigarettes during their lifetime) compared with 19.0% (95% CI: 12.1, 25.9) of male patients. The majority of male patients used to smoke and had been cigarette-free for at least 6 months prior to inclusion (75.0% [95% CI: 67.4, 82.7]), compared with over a quarter of female patients (26.8% [95% CI: 19.0, 34.7]). A higher proportion of female patients had exposure to passive smoking compared with male patients (12.2% [95% CI: 6.4, 18.0] and 0.7% [95% CI: 0.0, 2.1], respectively).

Clinical characteristics at inclusion

A summary of the lung function of patients with IPF reported at inclusion to the cohort is presented in Table 2. The mean forced vital capacity (FVC) percent predicted was statistically lower for male patients compared with female patients (77.7% [95% CI: 76.2, 79.3] and 87.4% [95% CI: 83.4, 91.4], respectively). The mean diffusing capacity of the lungs for carbon monoxide (DL_{CO}) percentage was 46.1% (95% CI: 44.6, 47.6) in males and 46.9% (95% CI: 44.2, 49.7) in females.

The mean GAP index score for the whole cohort at inclusion was 4.0. The proportion of male and female patients who were GAP Stage I was 30.2% (95% CI: 21.2, 39.1) and 67.3% (95% CI: 58.2, 76.5), respectively, whereas the proportion who were GAP Stage III was 17.3% (95% CI: 9.9, 24.7) and 1.0% (95% CI: 0.0, 2.9), respectively. The mean composite physiologic index (CPI) at inclusion for all patients was 47.0, and this was higher for male patients than female patients (47.6 [95% CI: 46.4, 48.8] and 43.8 [95% CI: 41.4, 46.1], respectively). The estimated extent of emphysema predicted using the combined pulmonary

fibrosis and emphysema (CPFE) index [16] was 5.0%, and was higher in female patients than male patients (7.1% [95% CI: 5.6, 8.5] and 4.5% [95% CI: 4.0, 5.1], respectively).

Further lung function data recorded at inclusion in RaDiCo-ILD are presented in **Supplementary Results**. The prominent markers of pulmonary functional impairment at inclusion to the cohort were significantly less severe for women than for men.

At cohort inclusion, the mean SF-36 physical and mental scores for the whole population were 52.4 (95% CI: 50.4, 54.3) and 56.8 (95% CI: 54.9, 58.7), respectively (**Table 3**). For male patients, the mean SF-36 physical and mental scores were 53.7 (95% CI: 51.6, 55.8) and 58.0 (95% CI: 56.0, 60.1), respectively. Both scores were numerically lower in female patients (45.7 [95% CI: 40.9, 50.6] and 50.6 [95% CI: 45.8, 55.4], respectively), indicating worse HRQoL.

The mean SGRQ total score was 42.6, with the greatest HRQoL impairment recorded in the activity score (56.4), followed by the symptom (49.3) and impact scores (34.9). The mean SGRQ total score was 41.5 (95% CI: 39.4, 43.6) for male patients and 48.5 (95% CI: 43.9, 53.0) for female patients, suggesting worse overall HRQoL for female patients. Male patients had SGRQ activity and impact scores of 54.8 (95% CI: 52.4, 57.2) and 34.0 (95% CI: 31.8, 36.2), respectively, which were also lower than the respective scores for female patients (64.6 [95% CI: 59.5, 69.7] and 39.1 [95% CI: 33.9, 44.3], respectively). However, SGRQ symptom scores were similar for both male and female patients (49.0 [95% CI: 47.1, 50.9] and 50.8 [95% CI: 46.8, 54.9], respectively).

Chest HRCT scans at inclusion

HRCT scans at inclusion revealed reticular abnormalities as the most common feature across the whole cohort, present in 97.6% of patients and prominent in 56.5% of patients (**Table 4**). Traction bronchiectasis was also present in almost all HRCT scans (95.2%), which may reflect diagnosis of probable IPF in line with the 2018 IPF classification [13].

Honeycombing was present in the HRCT scans of 66.2% of the total cohort and was present in a higher proportion of male patients (70.8% [95% CI: 61.0, 80.6]) than female patients (45.8% [95% CI: 35.1, 56.5]). There was a numerically higher proportion of male patients with prominent honeycombing compared with female patients (32.4% [95% CI: 22.4, 42.5] and 19.3% [95% CI: 10.8, 27.8], respectively). Emphysema was present in 20.5% of the total cohort and was more common in male patients than female patients (23.5% [95% CI: 14.4, 32.6] and 7.2% [95% CI: 1.7, 12.8], respectively). In the total cohort at cohort inclusion, 64.8% had ground-glass opacities on HRCT, present in 62.1% (95% CI: 51.6, 72.6) of male patients and 76.8% (95% CI: 67.7, 86.0) of female patients.

Prescribed medication at inclusion

A summary of the treatments for IPF reported at inclusion is presented in [Table 5](#). The median time between diagnosis and first treatment was 1.1 months (IQR: 0.0–3.7). The most prescribed first treatment during the time between diagnosis and cohort inclusion for the whole cohort was pirfenidone (36.1%), followed by nintedanib (29.2%). At diagnosis, 21.6% of patients received no treatment (20.6% and 26.5% for male and female patients, respectively). For 13.1% of patients with IPF, glucocorticoids were the first initiated treatment.

Discussion

We conducted an analysis of patients with IPF included in the multicentre RaDiCo-ILD registry in France over a 3-year period. In the present manuscript, we report a comprehensive summary of data recorded at inclusion from patients with IPF according to gender, in terms of demographics, clinical and radiological characteristics, HRQoL and treatment initiation at the time of study inclusion.

The present study enrolled 724 patients with IPF, of whom 83% were male, representing a higher proportion than those seen across other IPF registries [3, 8, 17, 10]. Patient gender bias at the time of IPF diagnosis is a topic of increasing interest, with a recent study by Assayag et al. demonstrating that male patients are more likely to receive a diagnosis of IPF compared with females, after adjusting for age, smoking history, environmental exposures and autoantibodies. This suggests that females may be under-diagnosed and males may be over-diagnosed with IPF [18]. An indirect, observational study that used data from the French hospital discharge database presented a very different picture of the IPF diagnosis disparity between genders in France, with a male population of 56.4% (n=3,650/6,467) [19]. Other large, national, epidemiological studies based on hospital databases in countries such as Finland, Italy and Denmark also demonstrated lower percentages of male patients than the RaDiCo-ILD cohort [20-23]. Despite study limitations with regards to the use of International Classification of Diseases codes to identify populations with IPF [19], which may present a risk of disease misclassification, the differences in gender distribution suggest that female patients may be under-diagnosed in the RaDiCo-ILD cohort. We speculate that this finding may be related to the low frequency of honeycombing as a prominent HRCT feature, as it is a key component of the usual interstitial pneumonia pattern on HRCT [13].

Registries have provided a wealth of information about the characteristics of patients with IPF. The RaDiCo-ILD registry included patients with IPF who had been treated in participating reference centres, representing the most severe and atypical cases; as such, it is difficult to compare our registry findings with those from other registries, especially given that each have their own population particularities. The Australian IPF Registry (AIPFR) included all patients with a diagnosis of IPF referred from their treating pulmonologist. Patients from the AIPFR had greater baseline lung function, with higher FVC%, DLCO% and longer 6MWT distance compared with patients with IPF in the RaDiCo-ILD cohort [3]. However, compared with the Pulmonary Fibrosis Foundation Patient Registry and a smaller

Swiss registry, which were also reference centre registries, RaDiCo-ILD patients had less impaired lung function at inclusion [24, 10].

Within the RaDiCo-ILD cohort of patients with IPF, there were no remarkable gender differences in age or time intervals between onset of symptoms and diagnosis, or between diagnosis and cohort inclusion. When compared with participants in EMPIRE, RaDiCo-ILD participants experienced a longer delay between the onset of symptoms and diagnosis [25]. They were also older at inclusion compared with other published IPF cohorts [26, 27, 3, 28, 29, 25], but younger compared with studies based on claims data [19, 30]. Hence, the RaDiCo-ILD cohort may better reflect the age of patients with IPF in the population, with less referral bias compared to other IPF registries.

The World Health Organization reports that the prevalence rate of current smokers in France is 31.9% according to the most recent nationally representative survey in 2017, with prevalence in men and women of 35.2% and 28.7%, respectively [31], but no data are available regarding ex-smokers. In our study, we found that 75% of male patients had a history of smoking, compared with 27% of female patients, representing a far greater gender disparity than in the general population today. However, our study represents an ageing population who are likely to have started smoking in the 1970's and 1980's when there were greater differences in the proportions of male and female smokers in France [32]. This high proportion of male smokers is in accordance with previous reports [24, 18, 5], including COFI, a national, multicentre, prospective IPF cohort with a study enrolment period of 2007–2010 [unpublished]. Of note, more than half of female patients with IPF had never smoked. Since smoking is known to be one of the main triggers in IPF pathophysiology, this could indicate different mechanisms of IPF occurrence in males and females.

Comorbidity prevalence was similar to previously reported registries, with GERD and arterial hypertension the most common comorbidities reported across both genders [24, 29, 10]. Coronary heart disease, diabetes and emphysema were more prevalent among males at study inclusion compared with women, whereas thyroid dysfunction, which was mostly

hypothyroidism, was more common among female patients. Given that female gender is a confounding factor for thyroid dysfunction, this finding was expected. The Swedish IPF registry demonstrated similar findings and showed that coronary heart disease was more prevalent in males regardless of smoking history, whereas thyroid diseases were more prevalent in ex-smoking females [8]. These differences likely reflect the imbalance of these conditions in the general population.

In the current study, males had lower FVC and forced expiratory volume in 1 second percent predicted at inclusion compared with females, suggesting a lung volume disadvantage that is consistent with previous reports [33, 8]. Interestingly, the difference is observed despite similar mean duration of symptoms before diagnosis between male and female patients. Although it is possible that female patients have an earlier perception of their symptoms, this could be associated with more extensive fibrosis in HRCT scans at diagnosis in male patients compared with females, especially since male patients had higher CPI scores (which reflect the extent of fibrosis on HRCT regardless of the emphysema extent). Despite the high prevalence of smoking history, a relatively low proportion of patients had emphysema on HRCT, as reflected by low values of CPFE index (which reflects the extent of emphysema on HRCT regardless of the extent of fibrosis). Female patients had significantly higher CPFE index scores compared with males, which suggests that the observation of greater lung volume in women compared with males in our cohort may be associated with more extensive emphysema. Overall, GAP index scores were higher for male patients than female patients, and more males were in GAP Stage III. The inclusion of male gender in the GAP index calculation may account for this gender imbalance, since male gender contributes one point to the index out of a maximum of eight [7].

Female patients had poorer HRQoL based on SF-36 and total SGRQ scores, despite having higher FVC at inclusion than male patients and similar DL_{CO}. Interestingly, our data suggest that men and women were similarly affected by IPF symptoms, although women were more acutely affected by psychosocial dysfunction (SGRQ impact score) and disruption of daily

physical activity (SGRQ activity score) than men. This discrepancy illustrates the multidimensional aspect of HRQoL in IPF. For instance, lung function decline, cough frequency, dyspnoea intensity, anxiety and depression all influence HRQoL in patients with IPF [34, 17]. This difference in HRQoL between genders has also been described for other chronic respiratory diseases such as chronic obstructive pulmonary disease [35].

Although reticulations were the most common imaging characteristics at cohort inclusion, there were some key gender discrepancies. Honeycombing was present in the chest scans of a greater proportion of male patients than females, while ground-glass opacities were present in a greater proportion of female scans. This study is one of few to have access to HRCT scans at inclusion, according to gender. In accordance with our data, the COFI cohort demonstrated a significant predominance of honeycombing and emphysema within the male population, although it was more prevalent overall [unpublished]. This may have contributed to gender imbalance in the RaDiCo-ILD cohort of patients with IPF, with honeycombing facilitating the non-invasive diagnosis of IPF in males.

Our study revealed that 22% of patients did not receive treatment at diagnosis; however, it is likely that some patients with good lung function and few symptoms may have only initiated treatment once disease progression was confirmed. More than half of patients (65%) received antifibrotic treatment at diagnosis, which reflected the availability of nintedanib and pirfenidone at the time of study enrolment. Glucocorticoids were prescribed to 13% of patients at diagnosis, which may represent the population with the most advanced disease, requiring palliation of symptoms.

As with any observational study, several potential biases are possible. Data bias was limited by the French organisation of reference and competence centres, which agreed to diagnose IPF in accordance with international and national guidelines defining a common diagnosis algorithm. Our study does not include data on the proportion of patients who had lung biopsies at diagnosis or were diagnosed with definite or probable IPF due to challenges collecting such data in a real-life cohort and the change in ATS/ERS IPF diagnosis criteria

during the course of patient inclusion. HRCT scans were obtained and analysed in each reference centre and were not systematically reviewed by a panel of radiologists; hence, it is possible that there are inconsistencies across centres. In addition, although HRCT scans were available for all patients at inclusion, there were missing data. Physician-associated selection bias is also possible, as patients included from the southern part of France are under-represented, with these centres being inactive due to administrative authorisation concerns. However, the most active French OrphaLung or RespiFIL centres participated and enrolled most of their patients with IPF, which should ensure the representativeness of selected centres and minimise bias.

Conclusions

In conclusion, our multicentre registry study conducted at reference centres throughout France provides further evidence of gender imbalance in lung volume and chest HRCT features at diagnosis of IPF, with male patients more likely to have emphysema, a greater lung volume reduction and more honeycombing on HRCT than female patients. Interestingly, our study suggests that female patients have a poorer HRQoL despite better lung volume, highlighting the multidimensional aspect of HRQoL in IPF.

Statements

Acknowledgements

Medical writing assistance was supported financially by RaDiCo and Boehringer Ingelheim and provided by Hannah Cook, PhD, of MediTech Media, under the authors' conceptual direction and based on feedback from the authors. Boehringer Ingelheim is an industrial supporter of the RaDiCo-ILD cohort. A full list of investigators is included in the

supplementary material. REDCap is a secure, web-based application from the Vanderbilt University, USA, designed to support data capture for research studies.

Statement of ethics

The registry was conducted in accordance with the ethical principles detailed in the Declaration of Helsinki, and written informed consent was obtained from all patients. The registry was approved by the ethical committee of the Inserm Institute, France on 6 October 2016 (approval no. IRB00003888) and the Commission Nationale de l'Informatique et des Libertés on 3 November 2016.

Conflict of interest statement

VC reports grants from Boehringer Ingelheim (BI); personal fees from Actelion, BI, Bayer/Merck, Sharp & Dohme (MSD), Novartis, Roche/Promedior, Sanofi, Celgene, Galapagos, Galecto, Shionogi and Astra Zeneca; and non-financial support from Roche/Promedior, Actelion and BI, outside the submitted work.

SG is an employee of RaDiCo and reports financial support of the RaDiCo-ILD cohort from BI during the conduct of the study.

SJ reports personal fees from Actelion, AIRB, Astra Zeneca, Bristol Myers Squibb (BMS), BI, Chiesi, Galacto Biotech, Gilead, GlaxoSmithKline (GSK), Lieven Van Landuyt Mediphar, Mundipharma, Novartis, Pfizer, Roche, Savara Pharmaceuticals and Genzyme. He is a clinical trial investigator for Bellorophon Therapeutics, Biogen, Pilant Therapeutics and Pharm-Olam, outside the submitted work.

HN reports grants from Roche/Genentech and BI; and personal fees from Roche/Genentech, BI and Galapagos. He is also a clinical trial investigator for Sanofi, Gilead, Novartis and Galecto Biotech, outside the submitted work.

433 BC reports grants from Astra Zeneca and BI; personal fees from Astra Zeneca, BI, Roche,
434 Sanofi, Genzyme and BMS; and non-financial support from Astra Zeneca, BI, Roche, Sanofi,
435 Genzyme and BMS, outside the submitted work.

436 PB reports personal fees from Roche, BI, Novartis, Teva and AstraZeneca. He has also
437 received congress travel fees and/or speaker honoraria from Roche, BI, Novartis, Chiesi,
438 Stallergene and Sanofi, outside the submitted work.

439 LWS reports personal fees from BI, Roche, BMS and Sanofi; and non-financial support from
440 BI and Roche, outside the submitted work.

441 MRG has nothing to disclose.

442 DIB has nothing to disclose.

443 JC has nothing to disclose.

444 SMA received congress travel fees and/or speaker honoraria from BI, Roche and Novartis,
445 outside the submitted work.

446 SQ has nothing to disclose.

447 SH has nothing to disclose.

448 DM reports grants from Actelion, Bayer and MSD; personal fees from Actelion, Bayer, GSK,
449 Pfizer, MSD, Chiesi, BI and Incyte Biosciences France; and non-financial support from MSD
450 and Acceleron, outside the submitted work.

451 ASG has nothing to disclose.

452 MC is an employee of RaDiCo and reports financial support of the RaDiCo-ILD cohort from
453 BI during the conduct of the study.

454 IDG is an employee of RaDiCo and reports financial support of the RaDiCo-ILD cohort from
455 BI during the conduct of the study.

456 SA reports grants from the Programme d'Investissements d'Avenir (PIA1) - Agence
457 Nationale de la Recherche, during the conduct of the study.

458 AC has nothing to disclose.

459 **Funding sources**

460 The RaDiCo-ILD cohort was implemented as part of the RaDiCo research programme,
461 funded by the French National Research Agency under the 'cohorts' program of the
462 Investissements d'Avenir (Investments for the Future) (ANR-10-COHO-0003) and
463 coordinated by the French national institute for Health and Medical Research (Inserm Unité
464 UMR S933, Hôpital Trousseau).

465 **Authors' contributions**

466 The authors meet the criteria for authorship as recommended by the International
467 Committee of Medical Journal Editors (ICMJE). All authors were involved in data collection,
468 in writing the manuscript, and read and approved the manuscript before submission.

469 Vincent Cottin and Isabelle Dufaure-Garé contributed to the data analysis and interpretation
470 of data and designed the study with Marie Chevereau.

471

References

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine*. 2011 Mar 15;183(6):788-824.
2. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. *New England Journal of Medicine*. 2018 May 10;378(19):1811-23.
3. Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. *Eur Respir J*. 2017 Feb;49(2):1601592.
4. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. *Eur Respir Rev*. 2020 Sep 30;29(157).
5. Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS. Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: A multicenter retrospective cohort study. *Chest*. 2020 Jul;158(1):245-51.
6. Ekstrom M, Gustafson T, Boman K, Nilsson K, Tornling G, Murgia N, et al. Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study. *BMJ Open*. 2014 Jan 9;4(1):e004018.
7. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med*. 2012 May 15;156(10):684-91.
8. Kalafatis D, Gao J, Pesonen I, Carlson L, Sköld CM, Ferrara G. Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden. *BMC Pulm Med*. 2019 Nov 27;19(1):222.
9. Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, et al. Patient registries in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*. 2019 Jul 15;200(2):160-67.
10. Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, et al. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. *Ann Am Thorac Soc*. 2020 Dec;17(12):1620-28.
11. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. *European Respiratory Journal*. 2015 Sep;46(3):795-806.
12. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet PY, Brauner M, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. *Eur Respir J*. 2017 Aug;50(2):1602419.

- 509 13. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of
510 idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J
511 Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68.
- 512 14. Lancaster LH. Utility of the six-minute walk test in patients with idiopathic pulmonary
513 fibrosis. Multidiscip Respir Med. 2018;13:45.
- 514 15. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, et al. The SF-36 and SGRQ:
515 Validity and first look at minimum important differences in IPF. Respiratory Medicine.
516 2010;104(2):296-304.
- 517 16. Wells AU, Jacob J, Cross G, Barnett J, Weycker D, Atwood M, et al. Development and testing
518 of a formula for predicting emphysema extent in patients with idiopathic pulmonary fibrosis.
519 American Journal of Respiratory & Critical Care Medicine. 2019;199:A2569.
- 520 17. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of
521 idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data
522 from the INSIGHTS-IPF registry. RespirRes. 2019 Mar 15;20(1):59.
- 523 18. Assayag D, Morisset J, Johansson KA, Wells AU, Walsh SLF. Patient gender bias on the
524 diagnosis of idiopathic pulmonary fibrosis. Thorax. 2020 May;75(5):407-12.
- 525 19. Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, et al. Burden of
526 Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS One.
527 2017;12(1):e0166462.
- 528 20. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial
529 idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in
530 Finland. Thorax. 2002 Apr;57(4):338-42.
- 531 21. Kornum JB, Christensen S, Grijota M, Pedersen L, Wogelius P, Beiderbeck A, et al. The
532 incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based
533 study. BMC Pulm Med. 2008 Nov 4;8:24.
- 534 22. Agabiti N, Porretta MA, Bauleo L, Coppola A, Sergiacomi G, Fusco A, et al. Idiopathic
535 Pulmonary Fibrosis (IPF) incidence and prevalence in Italy. Sarcoidosis Vasc Diffuse Lung Dis.
536 2014 Oct 20;31(3):191-7.
- 537 23. Harari S, Madotto F, Caminati A, Conti S, Cesana G. Epidemiology of Idiopathic Pulmonary
538 Fibrosis in Northern Italy. PLoS One. 2016 2016/02/03;11(2):e0147072.
- 539 24. Guler S, Zumstein P, Berezowska S, Pollinger A, Geiser T, Funke-Chambour M. Idiopathic
540 pulmonary fibrosis in a Swiss interstitial lung disease reference centre. Swiss Med Wkly.
541 2018;148:w14577.
- 542 25. Tran T, Šterclová M, Mogulkoc N, Lewandowska K, Müller V, Hájková M, et al. The European
543 MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic
544 pulmonary fibrosis. RespirRes. 2020 2020/01/08;21(1):11.

- 545 26. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients
546 with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. *Eur Respir J*.
547 2015 Jul;46(1):186-96.
- 548 27. Ferrara G, Carlson L, Palm A, Einarsson J, Olivesten C, Sköld M. Idiopathic pulmonary fibrosis
549 in Sweden: report from the first year of activity of the Swedish IPF-Registry. *Eur Clin Respir J*.
550 2016;3:31090.
- 551 28. Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry
552 (eurlPFreg): baseline characteristics and survival of patients with idiopathic pulmonary
553 fibrosis. *RespirRes*. 2018 Jul 28;19(1):141.
- 554 29. Wuyts WA, Dahlqvist C, Slabbynck H, Schlessen M, Gusbin N, Compere C, et al. Baseline
555 clinical characteristics, comorbidities and prescribed medication in a real-world population
556 of patients with idiopathic pulmonary fibrosis: the PROOF registry. *BMJ Open Respiratory*
557 *Research*. 2018;5(1):e000331.
- 558 30. Mortimer K, Hartmann N, Chan C, Norman H, Wallace L, Enger C. Characterizing idiopathic
559 pulmonary fibrosis patients using US Medicare-advantage health plan claims data. *BMC*
560 *Pulm Med*. 2019 Jan 10;19(1):11.
- 561 31. World Health Organization. Most recent nationally representative survey reporting
562 prevalence of tobacco use or smoking among adults. *Global Health Observatory data*
563 *repository*; 2020.
- 564 32. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking
565 prevalence and cigarette consumption in 187 countries, 1980-2012. *JAMA*. 2014 Jan
566 8;311(2):183-92.
- 567 33. Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J, et al. Sex differences in
568 physiological progression of idiopathic pulmonary fibrosis. *Eur Respir J*. 2008 Jun;31(6):1183-
569 88.
- 570 34. Glaspole IN, Chapman SA, Cooper WA, Ellis SJ, Goh NS, Hopkins PM, et al. Health-related
571 quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry.
572 *Respirology*. 2017 Jul;22(5):950-56.
- 573 35. Gut-Gobert C, Cavallès A, Dixmier A, Guillot S, Jouneau S, Leroyer C, et al. Women and
574 COPD: do we need more evidence? *Eur Respir Rev*. 2019 Mar 31;28(151).

575

Table 1. Patient characteristics at inclusion in the RaDiCo-ILD cohort

	Male (n=600)	Female (n=124)	Total (N=724)
Mean age, years \pmSD	72.1\pm8.5	73.3\pm8.7	72.3\pm8.5
95% CI	71.6, 72.8	72.9, 75.6	72.0, 73.1
Mean age at diagnosis, years \pmSD	70.7\pm8.6	72.1\pm9.1	70.9\pm8.7
95% CI	70.0, 71.3	70.5, 73.7	70.3, 71.5
Median time between diagnosis and inclusion, months (IQR)	8.5 (0.7–25.8)	5.0 (0.0–22.1)	7.8 (0.5–25.4)
Median time between first symptoms and diagnosis, years (IQR)	2.0 (1.0–4.0)	2.0 (1.0–4.0)	2.0 (1.0–4.0)
Missing, n	53	12	65
Mean BMI, kg/m² \pmSD	26.8\pm4.0	27.6\pm5.2	26.9\pm4.2
95% CI	26.4, 27.1	26.7, 28.6	26.6, 27.2
Arterial hypertension	255 (42.9)	60 (48.8)	315 (43.9)
95% CI	34.2, 51.7	40.0, 57.6	35.2, 52.7
Missing, n	6	1	7
Gastroesophageal reflux disease	150 (25.0)	41 (33.1)	191 (26.4)
95% CI	17.4, 32.6	24.8, 41.3	18.6, 34.1
Missing, n	11	2	13
Diabetes	147 (24.5)	22 (17.7)	169 (23.3)
95% CI	16.9, 32.1	11.0, 24.5	15.9, 30.8
Missing, n	11	3	14
Coronary disease	146 (24.6)	12 (9.8)	158 (22.0)
95% CI	17.0, 32.2	4.5, 15.0	14.7, 29.4
Missing, n	6	1	7
Emphysema^a	93 (17.0)	6 (5.4)	99 (15.0)

95% CI	10.0, 24.0	1.2, 9.6	8.4, 21.7
Missing, n	52	13	65
Thyroid dysfunction	35 (5.8)	28 (22.6)	63 (8.7)
95% CI	1.7, 10.0	15.2, 29.9	3.7, 13.7
Tobacco status			
Active	32 (5.3)	10 (8.1)	42 (5.8)
95% CI	1.4, 9.3	3.3, 13.0	1.7, 9.9
Passive	4 (0.7)	15 (12.2)	19 (2.6)
95% CI	0.0, 2.1	6.4, 18.0	0.0, 5.5
Prior smoker (at least 6 months)	450 (75.0)	33 (26.8)	483 (66.8)
95% CI	67.4, 82.7	19.0, 34.7	58.5, 75.1
Never^b	114 (19.0)	65 (52.9)	179 (24.8)
95% CI	12.1, 25.9	44.0, 61.7	17.1, 32.4
Lung biopsy	135 (22.9)	36 (29.5)	171 (24.1)
95% CI	15.5, 30.4	21.4, 37.6	16.5, 31.6
Missing, n	11	2	13

Data are n (%) unless otherwise stated.

^aReported as a comorbidity at registry inclusion.

^bDefined as having less than 100 cigarettes during lifetime.

BMI, body mass index; CI, confidence interval; IQR, interquartile range; RaDiCo-ILD, Rare Disease Cohort – Interstitial Lung Disease; SD, standard deviation.

Table 2. Lung function in patients with IPF at inclusion in the RaDiCo-ILD cohort

	Male (n=600)	Female (n=124)	Total (N=724)
FVC % predicted	77.7±19.3	87.4±22.5	79.4±20.2
95% CI	76.2, 79.3	83.4, 91.4	77.9, 80.9
DL_{CO} % predicted	46.1±16.8	46.9±13.9	46.2±16.4
95% CI	44.6, 47.6	44.2, 49.7	44.9, 47.5
Missing, n	86	23	109
FEV₁ % predicted	83.0±19.5	90.2±23.5	84.3±20.4
95% CI	81.5, 84.6	86.0, 94.4	82.8, 85.8
Missing, n	6	1	7
GAP index score	4.2±1.3	3.0±1.2	4.0±1.4
95% CI	4.1, 4.4	2.8, 3.2	3.9, 4.2
Missing, n	86	23	109
GAP stage, n (%)			
I	155 (30.2)	68 (67.3)	223 (36.3)
95% CI	21.2, 39.1	58.2, 76.5	26.9, 45.6
II	270 (52.5)	32 (31.7)	302 (49.1)
95% CI	42.8, 62.3	22.6, 40.8	39.4, 58.9
III	89 (17.3)	1 (1.0)	90 (14.6)
95% CI	9.9, 24.7	0.0, 2.9	7.7, 21.5
Missing, n	86	23	109
CPI	47.6±13.4	43.8±11.8	47.0±13.2
95% CI	46.4, 48.8	41.4, 46.1	45.9, 48.0
Missing, n	89	24	113
CPFE	4.5±7.1	7.1±8.0	5.0±7.3
95% CI	4.0, 5.1	5.6, 8.5	4.4, 5.5

6MWT, metres	414.0±130.3	346.5±117.5	402.9±130.6
95% CI	402.1, 425.9	322.2, 370.8	392.0, 413.7
Missing, n	134	32	166
Normalised 6MWT, % predicted	65.4±19.8	67.7±19.8	65.8±19.8
95% CI	63.5, 67.3	63.5, 71.9	64.1, 67.5
Missing, n	173	35	208

Data are mean±SD unless otherwise stated.

6MWT, 6-minute walk test; CI, confidence interval; CPFE, combined pulmonary fibrosis and emphysema; CPI, composite physiologic index; DL_{CO}, diffusing capacity for carbon monoxide; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; GAP, Gender, Age, Physiology; IPF, idiopathic pulmonary fibrosis; RaDiCo-ILD, Rare Disease Cohort – Interstitial Lung Disease; SD, standard deviation.

Table 3. HRQoL in patients with IPF at inclusion in the RaDiCo-ILD cohort

	Male	Female	Total
	(n=600)	(n=124)	(N=724)
SF-36 physical score	53.7±22.9	45.7±23.0	52.4±23.1
95% CI	51.6, 55.8	40.9, 50.6	50.4, 54.3
Missing, n	152	34	186
SF-36 mental score	58.0±22.4	50.6±23.3	56.8±22.7
95% CI	56.0, 60.1	45.8, 55.4	54.9, 58.7
Missing, n	142	31	173
SGRQ total score	41.5±21.5	48.5±20.1	42.6±21.4
95% CI	39.4, 43.6	43.9, 53.0	40.7, 44.5
Missing, n	194	48	242
SGRQ activity score	54.8±26.1	64.6±24.4	56.4±26.1
95% CI	52.4, 57.2	59.5, 69.7	54.2, 58.6
Missing, n	139	33	172
SGRQ symptom score	49.0±21.0	50.8±19.2	49.3±20.7
95% CI	47.1, 50.9	46.8, 54.9	47.5, 51.0
Missing, n	146	36	182
SGRQ impact score	34.0±24.2	39.1±25.2	34.9±24.4
95% CI	31.8, 36.2	33.9, 44.3	32.8, 36.9
Missing, n	139	30	169

Data are mean±SD unless otherwise stated.

CI, confidence interval; HRQoL, health-related quality of life; IPF, idiopathic pulmonary fibrosis; RaDiCo-ILD, Rare Disease Cohort – Interstitial Lung Disease; SD, standard deviation; SF-36, 36-Item Short Form survey; SGRQ, St. George's Respiratory Questionnaire.

599 **Table 4. Chest imaging results for patients at inclusion in the RaDiCo-ILD cohort**

	Male	Female	Total
Chest scans recorded^a	580	123	703
Reticular abnormalities			
Present	364 (98.1)	78 (95.1)	442 (97.6)
95% CI	95.2, 101.1	90.5, 99.8	94.2, 100.9
Present prominent	210 (56.6)	46 (56.1)	256 (56.5)
95% CI	45.9, 67.3	45.4, 66.8	45.8, 67.2
Missing, n	209	41	250
Bronchiectasis			
Present	356 (96.0)	76 (91.6)	432 (95.2)
95% CI	91.7, 100.2	85.6, 97.5	90.5, 99.8
Present prominent	43 (11.6)	10 (12.1)	53 (11.7)
95% CI	4.7, 18.5	5.0, 19.1	4.8, 18.6
Missing, n	209	40	249
Honeycombing			
Present	264 (70.8)	38 (45.8)	302 (66.2)
95% CI	61.0, 80.6	35.1, 56.5	56.1, 76.4
Present prominent	121 (32.4)	16 (19.3)	137 (30.0)
95% CI	22.4, 42.5	10.8, 27.8	20.2, 39.9
Missing, n	207	40	247
Emphysema			
Present	86 (23.5)	6 (7.2)	92 (20.5)
95% CI	14.4, 32.6	1.7, 12.8	11.8, 29.2
Present prominent	8 (2.2)	1 (1.2)	9 (2.0)
95% CI	0.0, 5.3	0.0, 3.6	0.0, 5.0
Missing, n	214	40	254

Ground glass opacity

Present	233 (62.1)	63 (76.8)	296 (64.8)
95% CI	51.6, 72.6	67.7, 86.0	54.4, 75.1
Present prominent	13 (3.5)	9 (11.0)	22 (4.8)
95% CI	0.0, 7.4	4.2, 17.7	0.2, 9.5
Missing, n	205	41	246

Data are n (%) unless otherwise stated.

^aThe chest scans of 4 patients were missing. HRCT scans were available for all patients but were not always recorded due to no physician interpretation.

CI, confidence interval; HRCT, high-resolution computed tomography; IPF, idiopathic pulmonary fibrosis; RaDiCo-ILD, Rare Disease Cohort – Interstitial Lung Disease.

Table 5. IPF treatment reported at inclusion in the RaDiCo-ILD cohort

	Male (n=600)	Female (n=124)	Total (N=724)
Median time between diagnosis and first treatment, months (IQR)	1.1 (0.0–3.8)	1.0 (0.0–3.1)	1.1 (0.0–3.7)
Missing, n	89	24	113
Treatment initiated at diagnosis^a			
Pirfenidone	213 (37.5)	36 (29.8)	249 (36.1)
Nintedanib	167 (29.4)	34 (28.1)	201 (29.2)
No drug	117 (20.6)	32 (26.5)	149 (21.6)
Glucocorticoids	71 (12.5)	19 (15.7)	90 (13.1)
Median oxygen delay, months (IQR)	2.4 (-1.1–21.8)	-0.5 (-9.4–10.8)	1.9 (-1.4–20.3)
Missing, n	10	1	11


Data are n (%) unless otherwise stated.

^aDefined as the first treatment during the time between diagnosis and inclusion in the cohort.

IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; RaDiCo-ILD, Rare Disease

Cohort – Interstitial Lung Disease.

Figure 1. Patient flow chart



^aPFT at inclusion visit completed for patients included up to 13 May 2020.

IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; PFT, pulmonary function test; RaDiCo-ILD, Rare Disease Cohort – Interstitial Lung Disease.

Supplementary Methods. Inclusion/exclusion criteria for the RaDiCo-ILD cohort

- Inclusion criteria:
 - Patient with a diagnosis of idiopathic interstitial pneumonia (IIP).
 - Clinical criteria:
 - Chronic respiratory insufficiency manifestations, including dyspnoea/tachypnoea, cough and cyanosis during exercise or at rest.
 - Radiological criteria:
 - Characteristic chest high-resolution computed tomography abnormalities, including widespread ground-glass opacity or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing.
 - Functional criteria:
 - Pulmonary function test abnormalities reflecting a restrictive pattern and including loss of lung volume, vital capacity, total lung capacity; reduction in diffusing capacity of the lungs for carbon monoxide, gas exchange abnormalities, and altered ventilatory response to exercise.
 - Patients affiliated to the “Régime National d'Assurance Maladie”.
- Exclusion criteria:
 - Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders.
 - Patients (parents/guardians for paediatric patients) not able to approve/understand the protocol.
- Participation in another study (clinical trial/non-interventional studies) is not an exclusion criterion of the RaDiCo-ILD cohort.

Supplementary Results. Additional lung function parameters in patients at inclusion in the RaDiCo-ILD cohort

	Male	Female	Total
	(n=600)	(n=124)	(N=724)
RV % predicted	83.6±30.1	89.4±30.5	84.7±30.2
95% CI	80.9, 86.4	83.6, 95.3	82.2, 87.2
Missing, n	136	17	153
KCO %	76.9±21.2	73.4±17.1	76.3±20.6
95% CI	75.0, 78.7	70.0, 76.8	74.7, 78.0
Missing, n	97	26	123
TLC, predicted	71.7±15.4	73.5±20.1	72.1±16.4
95% CI	70.4, 73.1	69.7, 77.2	70.7, 73.4
Missing, n	106	14	120
RV/TLC	1.2±4.8	3.2±15.1	1.6±7.8
95% CI	0.8, 1.6	0.3, 6.1	0.9; 2.2
Missing, n	118	15	133

Data are mean±SD unless otherwise stated.

CI, confidence interval; IPF, idiopathic pulmonary fibrosis; KCO; carbon monoxide transfer coefficient; RaDiCo-ILD, Rare Disease Cohort – Interstitial Lung Disease; RV, residual volume; SD, standard deviation; TLC, total lung capacity.

650 **Supplementary Table S1. Participating centres in the RaDiCo-ILD registry**

Participating centres	Investigators
Hôpital Louis Pradel, Lyon	Kaïs Ahmad Vincent Cottin Mouhamad Nasser Yasmine Rebaïne Julie Traclet Sabrina Zeghmar (research coordinator)
CHU Dijon-Bourgogne, Dijon	Guillaume Beltramo Philippe Bonniaud Maximilien Spanjaard
CHU Rennes, Rennes	Mallorie Kerjouan Alexandre Salé Cécile Daoudal Anne Marie Pilet Stéphane Jouneau
CHU Strasbourg, Strasbourg	Tristan Degot Sandrine Hirschi
Hôpital Avicenne, Paris	Hilario Nunes Yurdagül Uzunhan Dominique Valeyre Diane Bouvry Olivia Freynet Morgane Didier Aurélie Hervé Cecile Rotemberg Warda Khamis

	Florence Jeny
	Lucile Sesé
Hôpital Bichat, Paris	Bruno Crestani
CHU de Lille, Lille	Lidwine Wémeau-Stervinou
	Cécile Chenivresse
	Victor Valentin
	Victor Margelidon-Cozzolino
CHRU de Tours, Tours	Sylvain Marchand-Adam
	Gaelle Fajole
	Rabia Rouis-Bouabdallah
Hôpital Nord, Marseille	Martine Reynaud-Gaubert
	Ana Nieves
Hôpital Européen Georges Pompidou, Paris	Dominique Israël-Biet
	Jean Pastré
	Karine Juvin
Hôpital Tenon, Paris	Jacques Cadranel
	Jean-Marc Naccache
	Antoine Parrot
CHU Grenoble-Alpes, La Tronche	Sébastien Quétant
	Loic Falque
	Bruno Degano
	Gilbert Ferretti
Hôpital de Bicêtre, Le Kremlin Bicêtre	David Montani
	Marc Humbert
	Xavier Jaïs
CHU Montpellier	Anne-Sophie Gamez
	Arnaud Bourdin

651 RaDiCo-ILD, Rare Disease Cohort – Interstitial Lung Disease.

652